Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued
Reference number: GID-TA10418
The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for treating advanced or metastatic urothelial cancer.
For information, the company have announced that the Phase 3 KEYNOTE-361 trial evaluating pembrolizumab in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy and that company have no plans to submit for a Marketing Authorisation for this indication at this time.
Therefore NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.